COMPANY
J3 Bioscience
FDA-cleared device company Past trials only
Funding and NIH signals
- SEC Form D raise Raised $50K in debt securities (Form D filed Oct 16, 2026). SEC Form D 0001408012-26-000003 (Oct 16, 2026)
Evidence (1 event)
- Oct 16, 2026 · SEC Form D 0001408012-26-000003
Name of Issuer: J3 BIOSCIENCE, INC.; CIK: 1408012; Address: Salt Lake City, UT; Submission type: D; Filing date: 2026-10-16; Industry Group: Other Health Care; Date of First Sale: 2026-09-30; Types of Securities Offered: Debt, Option/warrant; Business combination transaction: false; Total Offering Amount: 50000; Total Amount Sold: 50000; Federal exemptions: 06b
- Oct 16, 2026 · SEC Form D 0001408012-26-000003
Timeline
- Partnership Partnership / licensing announced Nov 10, 2025. Source: company's own press page. source ↗
- Trial start Not phased (device or behavioral study): Efficacy of VR101 as a Personal Lubricant source ↗
- Trial start Not phased (device or behavioral study): Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness source ↗
- Trial start Early phase 1: Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness source ↗
Funding
- Partnership / licensing announced Nov 10, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT03150407 | Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness | Not phased (device or behavioral study) | Completed | May 1, 2017 | Aug 31, 2017 (actual) |
| NCT04288752 | Efficacy of VR101 as a Personal Lubricant | Not phased (device or behavioral study) | Completed | Feb 26, 2020 | May 1, 2020 (actual) |
| NCT02029053 | Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness | Early phase 1 | Completed | 2014-01 | 2014-05 (actual) |